The insurance ceiling price for asthma treatments containing ‘budesonide’ will be increased by up to 18.5%. The annual prescription market is expected to increase by more than KRW 1.5 billion. Once the supply and demand imbalance is resolved, the scope of market expansion is expected to increase further.

According to the Ministry of Health and Welfare on the 27th, the prices of Pulmican and Pulmicort will increase starting December 1. The price of Kuhnil Pharmaceutical's Pulmican will increase by 18.5% from KRW 946 to KRW 1,121. The price of AstraZeneca's Pulmicort will rise 12.5% from KRW 1,000 to KRW 1,125.

Pulmican and Pulmicort contain budesonide and are used to treat bronchial asthma